Jonathan Alspaugh - Aug 23, 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role: Chief Financial Officer
Signature: /s/ James Kastenmayer, by power of attorney
Stock symbol: AGLE
Transactions as of: Aug 23, 2022
Transactions value $: $0
Form type: 4
Date filed: 8/25/2022, 07:34 PM
Previous filing: Mar 15, 2022
Next filing: Feb 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGLE	Employee Stock Option (right to buy)	Award	$0	+130K		$0.00	130K	Aug 23, 2022	Common Stock	130K	$0.68	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.

Content

The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.